Rabbit Polyclonal PFN2 Antibody

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using SOD2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of Hela cells using SOD2 mouse mAb (green) and negative control (red).    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human ovarian cancer tissues using SOD2 mouse mAb with DAB staining.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human rectum cancer tissues using SOD2 mouse mAb with DAB staining.    

  
  

The profilin-2 (PFN2) antibody is a crucial tool in studying the role of profilin-2. a member of the profilin family of actin-binding proteins. Profilins regulate cytoskeletal dynamics by interacting with actin monomers and phosphoinositides, influencing cell motility, membrane trafficking, and signal transduction. Unlike the ubiquitously expressed profilin-1 (PFN1), PFN2 is predominantly found in the nervous system, particularly in neurons, where it modulates synaptic plasticity and neurotransmitter release. Its involvement in neurological disorders, such as Parkinson’s and Alzheimer’s disease, has driven research interest.

PFN2 antibodies are widely used to investigate protein expression, localization, and function in cellular and tissue contexts. They enable techniques like Western blotting, immunohistochemistry, and immunofluorescence, aiding in the characterization of PFN2’s role in neuronal development, synaptic function, and disease mechanisms. Studies have linked PFN2 dysregulation to aberrant actin polymerization, synaptic dysfunction, and neurodegenerative pathology.

Recent advances highlight PFN2’s interaction with pathogenic proteins (e.g., α-synuclein) and its potential as a biomarker or therapeutic target. However, antibody specificity remains critical, as PFN1/PFN2 structural similarities may lead to cross-reactivity. Validated PFN2 antibodies thus provide essential insights into neurobiology and disease pathways, bridging molecular mechanisms with clinical implications. Ongoing research continues to unravel its multifaceted roles in health and disease.